Comparative Pharmacology
Head-to-head clinical analysis: ERYPAR versus ERYTHROMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYPAR versus ERYTHROMYCIN.
ERYPAR vs ERYTHROMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erypoietin receptor agonist; stimulates erythropoiesis by binding to erythropoietin receptors on erythroid progenitor cells.
Binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis by blocking the translocation step.
Intravenous: 100 mg every 12 hours for 7 to 14 days.
250-500 mg orally every 6 hours or 500-1000 mg intravenously every 6 hours; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life is approximately 3-5 hours in adults with normal renal function; may be prolonged to >10 hours in severe renal impairment
Clinical Note
moderateErythromycin + Norfloxacin
"Erythromycin may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateErythromycin + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Erythromycin."
Clinical Note
moderateErythromycin + Ibandronate
"Erythromycin may increase the QTc-prolonging activities of Ibandronate."
Clinical Note
moderateErythromycin + Indapamide
Terminal half-life is 1.4-2 hours in adults with normal renal function; may be prolonged to 5-6 hours in anuria.
Primarily renal excretion of unchanged drug (~75%) and metabolites; biliary/fecal elimination accounts for ~20%
Primarily hepatic (biliary) elimination; approximately 2-5% excreted unchanged in urine, 30-60% excreted in feces via bile.
Category C
Category A/B
Macrolide Antibiotic
Macrolide Antibiotic
"Erythromycin may increase the QTc-prolonging activities of Indapamide."